Jazz Singing A Stronger Oncology Tune Through Celator Buy

Jazz has added to its oncology portfolio through a $1.5bn purchase of Celator Pharmaceuticals – developer of acute myeloid leukemia drug, Vyxeos (cytarabine/daunorubicin liposome injection).

pills

Ireland-headquartered Jazz Pharmaceuticals PLC will pay $30.25 per share in cash, or approximately $1.5bn, to acquire small US pharma Celator Pharmaceuticals Inc. for its lead cancer therapy, Vyxeos.

As the rest of Celator's pipeline appears void of other smash hits, Vyeos could be a number one for Jazz....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip